Girshick Birgit sold $1.8M of CRL
Girshick Birgit (Chief Executive Officer) sold 6,500 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $279.90 ($1.82M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market sale details: 6,500 shares at $279.90, total $1,819,350, with holdings after sale of 36,013 shares, executed under a pre-arranged 10b5-1 plan.
Market read
This provides a fresh datapoint on insider activity but no new fundamental catalyst for CRL.
What to watch
Insider sales can be routine under 10b5-1 plans; traders should compare with prior Form 4 patterns and whether any other executives filed concurrent transactions.
Background
The article is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc.
Ticker impact
Charles River Laboratories CEO Girshick Birgit filed a Form 4 selling 6,500 shares at $279.90 on 2026-08-11 under a 10b5-1 plan.
Likely limited near-term impact; watch for follow-on insider activity or other company-specific catalysts.
The filing discloses the transaction size and price, but it does not include new operational, financial, or regulatory information. The presence of a 10b5-1 plan reduces interpretive weight.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
The sale could be purely liquidity-driven even if not perfectly timed to fundamentals, so it may not reflect bearish expectations.
Key entities
- issuerCHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Subject of the Form 4 insider transaction disclosure.
- insiderGirshick Birgit
CEO and officer/director who sold shares.
